Neuren logo

2013 Annual Report

Now available
› Download (PDF, 3.47MB)

Welcome to Neuren

A novel and dynamic biopharmaceutical company developing human therapies for neuroprotection and metabolic related disorders.


Recent announcements

27 March 2014
Notice of Annual Shareholders' Meeting

27 February 2014
Neuren reports financial results for 2013

28 January 2014
Neuren reports progress in its NNZ-2566 clinical trial programs

› View more announcements

Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury and concussion, as well as chronic conditions such as Rett Syndrome and Fragile X Syndrome.

Neuren has NNZ-2566 presently in clinical development to treat three different neurological conditions, and NNZ-2591 in preclinical development for chronic neurodegenerative conditions.

Neuren is listed on the Australian Securities Exchange (ASX: NEU).

Unsupported Listings:

Neuren is aware of listings of securities on the Berlin Stock Exchange (code: NK9.BE) and in the US “Over the Counter” market (code: NURPF.PK). These securities have not been issued by Neuren and are not recorded in the Neuren share register. If you wish to trade in securities issued by Neuren you should ensure that they are acquired or sold through the Australian Securities Exchange (ASX code: NEU) which is the only listing supported by the Company. 


    ©2008 Neuren Pharmaceuticals Limited